Clinical bottom line
Biomarker testing in solid tumors continues to evolve rapidly, with updated recommendations emphasizing comprehensive molecular profiling to guide precision oncology. Liquid biopsy has gained consensus as a valuable tool for advanced non-small cell lung cancer (NSCLC), complementing tissue testing when biopsy is limited or infeasible. In colorectal and prostate cancers, expanding biomarker panels including RAS, BRAF, and PTEN alterations inform targeted therapies and prognostication. Despite advances, variability in testing adoption and interpretation challenges remain, underscoring the need for standardized protocols and multidisciplinary collaboration (Rolfo et al., 2021; Taieb et al., 2019; Epstein et al., 2021).
What the evidence shows
Rolfo et al. (2021) present an international consensus on liquid biopsy use in advanced NSCLC, endorsing circulating tumor DNA (ctDNA) analysis for detecting actionable mutations such as EGFR, ALK, and ROS1 when tissue is insufficient or inaccessible. This approach facilitates timely treatment decisions and monitoring of resistance mutations.
Taieb et al. (2019) review the evolving biomarker landscape in metastatic colorectal cancer, highlighting the importance of extended RAS and BRAF testing to select candidates for anti-EGFR therapy and emerging markers like microsatellite instability (MSI) for immunotherapy eligibility.
Epstein et al. (2021) provide updated grading and biomarker recommendations in prostate cancer, emphasizing molecular alterations including PTEN loss, which has prognostic and therapeutic implications. Fusco et al. (2020) further discuss PTEN alterations across cancers, noting their role in resistance mechanisms and as potential targets.
Bowman et al. (2021) report trends in biomarker testing across early-stage solid tumors, revealing increased adoption but persistent gaps in comprehensive profiling, particularly in community settings.
Caveats and uncertainty
Heterogeneity in testing platforms, assay sensitivity, and reporting standards complicate result interpretation.
Liquid biopsy sensitivity varies with tumor burden and shedding rates, potentially yielding false negatives.
Access to comprehensive molecular testing remains uneven globally, influenced by cost and infrastructure.
Clinical utility of some emerging biomarkers requires further validation in prospective trials.
Integration of biomarker data into treatment algorithms demands multidisciplinary expertise.
How this may change practice
Pathologists and oncologists should incorporate updated biomarker panels into routine diagnostic workflows for solid tumors, prioritizing comprehensive genomic profiling.
Liquid biopsy offers a minimally invasive alternative or complement to tissue biopsy in advanced NSCLC and potentially other cancers.
Standardization of testing methodologies and reporting will enhance result reliability and clinical decision-making.
Education and collaboration across specialties are essential to interpret complex biomarker data and optimize personalized treatment.
Health systems should address barriers to equitable access to biomarker testing to improve outcomes.